Upstream Bio reported a quarterly loss of $0.75 per share, slightly better than the Zacks Consensus Estimate of a $0.80 loss. The result still reflected a year-over-year deterioration from a $0.51 loss per share a year ago. Overall, this is a modest earnings update with limited immediate market impact.
Upstream Bio reported a quarterly loss of $0.75 per share, slightly better than the Zacks Consensus Estimate of a $0.80 loss. The result still reflected a year-over-year deterioration from a $0.51 loss per share a year ago. Overall, this is a modest earnings update with limited immediate market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
